Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Model-informed precision dosing study for posaconazole in invasive aspergillosis
ChiCTR2600133026Phase 4Recruiting
- Sponsor
- Huashan Hospital
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of posaconazole in invasive aspergillosis (IA), sponsored by Huashan Hospital. Primary endpoints: Predictive performance of the existing PopPK model and Posaconazole population PK parameter estimates. Started Jun 2026; status: recruiting.
02
Drugs
posaconazole
03
Conditions
invasive aspergillosis (IA)
Beyond the preview
Go deeper on ChiCTR2600133026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600133026.